Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AstraZeneca Plc (NYSE: AZN).

Full DD Report for AZN

You must become a subscriber to view this report.


Recent News from (NYSE: AZN)

Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans
Analysis focus: OMER Omeros (NASDAQ: OMER ) is moving towards a rolling BLA submission for OMS721. On this good news, and despite tepid Q1 results, investors are becoming increasingly bullish the stock, as seen by its sudden 23% spike on the news of the BLA submission. OMS721 is in tri...
Source: SeekingAlpha
Date: May, 14 2018 10:00
AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Recently, it was announced that AstraZeneca ( AZN ) had failed a phase 3 study treating patients with chronic obstructive pulmonary disease (COPD). This is a huge blow to the big pharma, but not all is lost because it still has another shot on goal for this indication from another phase 3 st...
Source: SeekingAlpha
Date: May, 14 2018 01:50
Week In Review: $3.4 Billion Week For China Life Science Deals
Deals and Financings Armo BioSciences (ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO...
Source: SeekingAlpha
Date: May, 13 2018 11:40
AstraZeneca's benralizumab flunks late-stage COPD study
AstraZeneca (NYSE: AZN ) announces that a Phase 3 clinical trial, GALATHEA , evaluating asthma med Fasenra (benralizumab) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) failed to demonstrate a statistically valid decrease in exacerbations, the primary e...
Source: SeekingAlpha
Date: May, 11 2018 08:36
3 Things In Biotech, May 10: AstraZeneca Expands, Roche Digs In, OncoSec Gets A Collab
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: May, 11 2018 08:00
Novo Nordisk: An Objective Analysis
In January 2017 I analyzed the major pharmaceuticals sector which resulted in a buy recommendation for Novo Nordisk. The analysis included a target price, which was hit in September. I looked at the company again in October and new financials led to a new valuation, and as it turned out, a n...
Source: SeekingAlpha
Date: May, 08 2018 10:48
Iterum Therapeutics Plans $92 Million IPO
Quick Take Iterum Therapeutics ( ITRM ) intends to raise $92 million in an IPO from the sale of its common stock, according to an S-1 regulatory filing . The firm is a late clinical-stage biopharma developing treatments for urinary tract and intra-abdominal infections. ITRM is enhanci...
Source: SeekingAlpha
Date: May, 07 2018 12:02
No, Sweden Is Not A Socialist Country. Invest With Caution Anyway.
By now I hope readers recognize that your humble author is an equal opportunity iconoclast. When it comes to political debate there are no guiltless parties (no pun intended). Myths and half-truths are believed and spread by all manner of politicos, ideologues, and media pundits, some innocent...
Source: SeekingAlpha
Date: May, 06 2018 13:05
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve...
Source: SeekingAlpha
Date: May, 05 2018 08:33
Kiniksa Pharmaceuticals Files For $100 Million IPO
Quick Take Kiniksa Pharmaceuticals (KNSA) intends to sell Class A shares for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapies for a range of inflammatory and autoimmune diseases in cardiac and skin conditions. ...
Source: SeekingAlpha
Date: May, 04 2018 12:33

 


About AstraZeneca Plc (NYSE: AZN)

Logo for AstraZeneca Plc (NYSE: AZN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $23,027,175,517 - 05/11/2018
  • Issue and Outstanding: 632,614,712 - 12/31/2016

 


Recent Filings from (NYSE: AZN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018

 

 


Daily Technical Chart for (NYSE: AZN)

Daily Technical Chart for (NYSE: AZN)


Stay tuned for daily updates and more on (NYSE: AZN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: AZN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AZN and does not buy, sell, or trade any shares of AZN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/